Last reviewed · How we verify
Bucloxonic Acid (BUCLOXIC ACID)
Bucloxonic Acid (generic name: BUCLOXIC ACID) is a bucloxic acid drug. It is currently in Phase 2 development.
Bucloxonic Acid is thought to work by modulating a specific molecular target, although the exact mechanism is currently unknown.
Bucloxonic Acid (BUCLOXIC ACID) is a small molecule drug in the bucloxic acid class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Bucloxonic Acid is unclear, with unknown patent status and generic manufacturers. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to determine the potential therapeutic applications and risks associated with this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BUCLOXIC ACID |
|---|---|
| Drug class | bucloxic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and Bucloxonic Acid is a key that fits into one of those locks. When it binds, it can either turn the lock open or closed, depending on the specific target it's interacting with. This can affect how cells behave and communicate with each other, potentially leading to changes in various bodily functions.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bucloxonic Acid CI brief — competitive landscape report
- Bucloxonic Acid updates RSS · CI watch RSS
Frequently asked questions about Bucloxonic Acid
What is Bucloxonic Acid?
How does Bucloxonic Acid work?
What is the generic name of Bucloxonic Acid?
What drug class is Bucloxonic Acid in?
What development phase is Bucloxonic Acid in?
Related
- Drug class: All bucloxic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing